Information  X 
Enter a valid email address
  Print      Mail a friend       More announcements

Friday 21 February, 2020

T.Rowe Price Assoc

Form 8.3 - [AbbVie Inc]

RNS Number : 7826D
T.Rowe Price Associates
21 February 2020
 

Ap19

 

FORM   8.3

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

 

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

 

1.  KEY   INFORMATION

 

Nameofpersondealing (Note 1)

 T. ROWE PRICE ASSOCIATES, INC.

Companydealtin

 ABBVIE INC

Classofrelevantsecuritytowhichthe dealingsbeingdisclosedrelate (Note 2)

Date of dealing

  20 February 2020

2.  INTERESTS AND SHORT POSITIONS

 

(a)  Interests   and   short   positions   (following   dealing)   in   the   class   of   relevant   security   dealt   in   (Note   3)

 

Long

Short

 

Number

 

(%)

Number

 

(%)

(1)Relevantsecurities

 42,485,913   2.87%

 

(2) Derivatives (other than options)

 

 

(3)Optionsandagreementstopurchase/sell

 

 

Total

 42,485,913   2.87%

 

             

 

(b)  Interests and short positions in relevant securities of the company, other than the class dealt in  (Note   3)

Classofrelevantsecurity:

Long

Short

 

Number

 

(%)

Number

 

(%)

(1)Relevantsecurities

 

 

 

(2) Derivatives (other than options)

 

 

 

(3)Optionsandagreementstopurchase/sell

 

 

Total

 

 

             

 

Ap20

 

 

1.  DEALINGS  (Note   4)

 

(a)  Purchases and sales

 

 

Purchase/sale

 

Numberofrelevantsecurities

 

Priceperunit (Note 5)

Purchases

 

 

 

 

 

 

Sales

 

 

 

921

200

2,365

1,026

51,417

7,851

469

500

 

93.950 USD

93.975 USD

94.055 USD

94.147 USD

94.160 USD

94.201 USD

94.230 USD

93.470 USD

 

 

 

 

 

 

 

 

(b)  Derivatives transactions (other than options transactions)

 

Productname,

e.g. CFD

Natureoftransaction

(Note 6)

Numberofrelevantsecurities

(Note 7)

Priceperunit

(Note 5)

 

 

 

 

 

(c)  Options transactions in respect of existing relevant securities

 

 

(i)  Writing, selling, purchasing or varying

 

Productname,

e.g. call option

Writing, selling,purchasing,varyingetc.

Numberofsecurities towhichtheoptionrelates (Note 7)

Exercise price

Type, e.g.American,Europeanetc.

Expiry date

Optionmoney paid/receivedperunit (Note 5)

 

 

 

 

 

 

 

 

(ii)  Exercising

 

Productname,

e.g. call option

Numberofsecurities

Exercisepriceper unit (Note 5)

 

 

 

 

(d)  Other dealings (including transactions in respect of new securities) (Note 4)

 

Nature of transaction

(Note 8)

Details

Price per unit

(if applicable) (Note 5)

 

 

 

 

Ap21

 

2.  OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 

 

 

 

Full details of any agreement, arrangement or understanding between the person disclosing and any 

other person relating to the voting rights of any relevant securities under any option referred to on this 

form   or   relating   to   the   voting   rights   or   future   acquisition   or   disposal   of   any  relevant securities to which 

any derivative referred to on this form is referenced. If none, this should be stated.

 

 

 

 

 

 

 

 

 

 

Is a Supplemental Form 8 attached?  (Note   9)    NO

 

Dateofdisclosure

 21 February 2020

Contact name

 Gary Greb

Telephone number

 001 410 345 2527

If aconnectedEFM,nameofofferee/offerorwithwhichconnected

 

If aconnectedEFM,statenatureofconnection (Note 10)

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected]om or visit www.rns.com.
 
END
 
 
ISEUAOORRRUUUAR

a d v e r t i s e m e n t